Remove Financial Institution Remove Middle Market Remove Valuation
article thumbnail

PCE Welcomes Bradley Scharfenberg as Vice President, M&A

PCE

Brad joins us with over a decade of investment banking experience, having advised on more than 30 middle-market M&A transactions across healthcare, consumer, and industrial sectors.

M&A 52
article thumbnail

The Full Guide to Healthcare Private Equity, from Careers to Contradictions

Mergers and Inquisitions

Mispriced Companies and Assets – Some mature healthcare firms trade at low valuation multiples , often because the market misunderstands their contracts, revenue, or track record. Upper-Middle-Market and Middle-Market Firms with Healthcare Teams – It’s the same idea, but they’re smaller and do smaller deals.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ESOPs Are an Exit Alternative

Focus Investment Banking

First, the valuation you get can be very fair,” says Beard. And by the way, this valuation is always negotiated. In a non-ESOP company, if I'm a bank or a financial institution that has lent you money and something goes awry, generally we can sit down and figure out a way to deal with it.

Debt 52
article thumbnail

Cooley’s 2023 Tech M&A Year in Review: An AI-Generated Glass Half Full

Cooley M&A

Private equity slowed but not stopped by financing environment Despite record amounts of dry powder accumulating for sponsors, high financing costs, persistent valuation gaps and a closed tech IPO market led to a significant decrease in private equity M&A activity in 2023.

M&A 59